On a tumultuous trading day, Eli Lilly and Co. (LLY) showcased a dramatic stock performance that belied its closing uptick. Starting the day with high hopes, the stock surged to a peak before plunging ...

A failure by both sides to reach an agreement had left patients in limbo.

What RFK Jr.'s plan to change medical journals could mean for your health On a recent weekday evening, Ashly Richards helped her 13-year-old son, Case, with homework. He did math problems and some ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in ...

Lilly's weight-loss drug Zepbound leads the U.S. market and has faced less competition from cheaper copies made by compounding pharmacies, giving it an edge, they said, after investors wiped $70 ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races. Image source: Getty Images.

In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races. Where to invest $1,000 right now?